OncoMatch/Clinical Trials/NCT06172595
FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma
Is NCT06172595 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for glioma, malignant.
The goal of this clinical trial is to evaluate the performance characteristics of O-(2-\[18F\]fluoroethyl)-L-tyrosine (FET) PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional imaging and determine the sensitivity and specificity of \[18F\]FET-PET in delineating disease. The main question\[s\] it aims to answer are: * whether 18F-FET-PET will demonstrate high diagnostic accuracy to detect true tumour progression * whether we can optimise the threshold cut-offs for TBRmax and other relevant parameters in discriminating pseudoprogression and disease progression Participants will undergo a limited 18F-FET PET/CT of the brain in SGH.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Required: IDH2 wild-type
Disease stage
Required: Stage WHO GRADE III, WHO GRADE IV (WHO)
Excluded: Stage WHO GRADE I, WHO GRADE II
malignant glioma (defined as WHO grade III or IV); Low-grade gliomas (histology grade 1 or 2 by WHO classification) [excluded]
Demographics
Prior therapy
Must have received: radiation therapy
previous RT to tumour
Cannot have received: vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments (bevacizumab)
Previous bevacizumab or other vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06172595 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior vascular endothelial growth factor (VEGF) targeting agents or anti-angiogenic treatments disqualifies patients from enrollment.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
Does this trial require IDH2?
Yes, IDH2 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage WHO GRADE III or WHO GRADE IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages